Literature DB >> 10966281

Comparison of hyperventilation and inhaled nitric oxide for pulmonary hypertension after repair of congenital heart disease.

K Morris1, M Beghetti, A Petros, I Adatia, D Bohn.   

Abstract

BACKGROUND: Pulmonary hypertension is associated with congenital heart lesions with increased pulmonary blood flow. Acute increases in pulmonary vascular resistance (PVR) occur in the postoperative period after repair of these defects. These increases in PVR can be ablated by inducing an alkalosis with hyperventilation (HV) or bicarbonate therapy. Studies have shown that these patients also respond to inhaled nitric oxide (iNO), but uncertainty exists over the relative merits and undesirable effects of HV and iNO. HYPOTHESIS: Alkalosis and iNO are equally effective in reducing PVR and pulmonary artery pressure (PAP) in children with pulmonary hypertension after open heart surgery.
SETTING: Critical care unit of a tertiary care pediatric hospital.
DESIGN: Prospective, randomized, crossover design. PATIENTS: Twelve children with a mean PAP > 25 mm Hg at normal pH after biventricular repair of congenital heart disease.
INTERVENTIONS: Patients were assigned to receive iNO or HV (pH > 7.5) in random order, and the effect on hemodynamics was measured. Each treatment was administered for 30 mins with a 30-min washout period between treatments. Finally, both treatments were administered together to look for a possible additive effect.
MEASUREMENTS AND MAIN RESULTS: Cardiac output and derived hemodynamic parameters using the dye dilution technique. Hyperventilation, achieved by an increase in ventilator rate without a change in mean airway pressure, decreased Pa(CO2) from a mean (SD) of 43.7+/-5.3 to 32.3+/-5.4 mm Hg and increased pH from 7.40+/-0.04 to 7.50+/-0.03. This significantly altered both pulmonary and systemic hemodynamics with a reduction in PAP, PVR, central venous pressure, and cardiac output and an increase in systemic vascular resistance. In comparison, iNO selectively reduced PAP and PVR only. The reduction in PVR was comparable between treatments, although addition of iNO to HV resulted in a small additional reduction in PVR. An additional decrease in PAP was seen when HV was added to iNO, attributable to a reduction in cardiac output rather than a further decrease in PVR.
CONCLUSIONS: Inhaled NO and HV are both effective at lowering PAP and PVR in children with pulmonary hypertension after repair of congenital heart disease. The selective action of iNO on the pulmonary circulation offers advantages over HV because a decrease in cardiac output and an increase in SVR are undesirable in the postoperative period.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10966281     DOI: 10.1097/00003246-200008000-00048

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  15 in total

Review 1.  Review of inhaled nitric oxide in the pediatric cardiac surgery setting.

Authors:  Paul A Checchia; Ronald A Bronicki; Brahm Goldstein
Journal:  Pediatr Cardiol       Date:  2012-04       Impact factor: 1.655

2.  Part 10: Pediatric basic and advanced life support: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations.

Authors:  Monica E Kleinman; Allan R de Caen; Leon Chameides; Dianne L Atkins; Robert A Berg; Marc D Berg; Farhan Bhanji; Dominique Biarent; Robert Bingham; Ashraf H Coovadia; Mary Fran Hazinski; Robert W Hickey; Vinay M Nadkarni; Amelia G Reis; Antonio Rodriguez-Nunez; James Tibballs; Arno L Zaritsky; David Zideman
Journal:  Circulation       Date:  2010-10-19       Impact factor: 29.690

3.  Pediatric basic and advanced life support: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations.

Authors:  Monica E Kleinman; Allan R de Caen; Leon Chameides; Dianne L Atkins; Robert A Berg; Marc D Berg; Farhan Bhanji; Dominique Biarent; Robert Bingham; Ashraf H Coovadia; Mary Fran Hazinski; Robert W Hickey; Vinay M Nadkarni; Amelia G Reis; Antonio Rodriguez-Nunez; James Tibballs; Arno L Zaritsky; David Zideman
Journal:  Pediatrics       Date:  2010-10-18       Impact factor: 7.124

4.  Mechanical ventilation strategy following Glenn and Fontan surgeries: On going challenge!

Authors:  Ayman Al-Eyadhy
Journal:  J Saudi Heart Assoc       Date:  2009-08-15

5.  Our paper 20 years later: Inhaled nitric oxide for the acute respiratory distress syndrome--discovery, current understanding, and focussed targets of future applications.

Authors:  R Rossaint; K Lewandowski; W M Zapol
Journal:  Intensive Care Med       Date:  2014-09-09       Impact factor: 17.440

6.  Postoperative Inhaled Nitric Oxide Does Not Decrease Length of Stay in Pediatric Cardiac Surgery Admissions.

Authors:  Joshua Wong; Rohit S Loomba; Lee Evey; Ronald A Bronicki; Saul Flores
Journal:  Pediatr Cardiol       Date:  2019-08-24       Impact factor: 1.655

Review 7.  Inhaled nitric oxide and related therapies.

Authors:  Frederick E Barr; Duncan Macrae
Journal:  Pediatr Crit Care Med       Date:  2010-03       Impact factor: 3.624

Review 8.  Pharmacologic management of perioperative pulmonary hypertension.

Authors:  Julie W Cheng; Adriano R Tonelli; Gosta Pettersson; Richard A Krasuski
Journal:  J Cardiovasc Pharmacol       Date:  2014-04       Impact factor: 3.105

9.  Hyperventilation versus standard ventilation for infants in postoperative care for congenital heart defects with pulmonary hypertension.

Authors:  Takako Umenai; Nobuaki Shime; Satoru Hashimoto
Journal:  J Anesth       Date:  2009-02-22       Impact factor: 2.078

10.  Clinical perspectives with long-term pulsed inhaled nitric oxide for the treatment of pulmonary arterial hypertension.

Authors:  Robyn J Barst; Richard Channick; Dunbar Ivy; Brahm Goldstein
Journal:  Pulm Circ       Date:  2012 Apr-Jun       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.